ARA-290
Also known as: Cibinetide
An erythropoietin-derived peptide for tissue protection without erythropoietic effects.
Overview
ARA-290 is an 11-amino acid peptide derived from the tissue-protective region of erythropoietin. It activates the innate repair receptor without stimulating red blood cell production.
Mechanism of Action
Activates the innate repair receptor (IRR), a heterodimer of EPO-R and CD131. Promotes tissue protection and repair through anti-inflammatory and anti-apoptotic pathways.
Pharmacokinetics
Short half-life requiring daily dosing. Good tissue distribution.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Standard
4 mg
Once daily
28 days
Clinical trial protocol
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Improved small fiber neuropathy symptoms in clinical trials
- 2Reduced neuropathic pain scores
- 3Anti-inflammatory effects without erythropoiesis
- 4Potential in diabetic complications
Side Effects & Contraindications
Reported Side Effects
- Injection site reactions
- Headache
Contraindications
- Active malignancy
Safety Considerations
Well-tolerated in clinical trials. No erythropoietic effects observed.
Storage Requirements
Store at 2-8C
Scientific References
- 1